Feeds:
Posts
Comments

Posts Tagged ‘Rapamune’

*****

TODAY’S NEWS:

Very big news for Vertex75% of hepatitis C patients never treated before achieved a viral cure after receiving a 12-week course of the company’s experimental drug telaprevir plus the current standard of care, according to results from a phase III studymore

Genzyme’s Pompe remedy approved by FDA; meanwhile, more detail on their consent decree.

More on alleged Wyeth tactics to promote Rapamune off-label. If true, yuck! Gold-in Rule at work.

Connecticut passes new pharma ethics code.

Part 2 of my interview over at MessagingLab blog (by Karl Schmieder): Pharma, Social Media, and the FDA.

RECOMMENDED

Coaching skills. Your field managers and other leaders are constantly in need of improvement here.  And we have great partners to recommend for coaching programs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media in Pharma stuff today: An “Ultimate Guide to Facebook“, from our friends over at Pixels and Pills. And, reporting adverse events on social media. More? Sure – comparing how pharma companies are using social media currently (from @healthcarengage). Even more? OK, you asked for it – Social Media and Celebrities in pharma (from John Mack’s blog)

JUST FOR FUN

Examples of Lightning Photography. Stunningly beautiful.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

Watson gets FDA approval to start shipping generic Valtrex.

Novartis oral MS drug – FDA extends review another 3 months – Novartis will have to wait a bit longer in its bid to get the first oral treatment for multiple sclerosis on the market after regulators in the USA put back a review of Gilenia. The US Food and Drug Administration has extended by three months, to September, its review period for Gilenia (fingolimod), previously known as FTY720more

Genzyme: Big fine, big changes to get manufacturing back under control.

Another day, another whistleblower suit comes to light. This time, Wyeth and Rapamune promotion for unapproved uses.

Layoffs at Quintiles.

RECOMMENDED

Train-the-Trainer. Your new trainers have whole new sets of skills (curriculum design, ISD, project management, presentation, etc.) – we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Three “I’s” of Tomorrow’s Successful Company. An important perspective from Dennis Urbaniak (VP U.S. Diabetes, Sanofi-Aventis). Titles, Budgets, and Staff are out – Ideas, Initiative, and Inspiration are in.

JUST FOR FUN

50 Beautiful Examples of Architecture Photography.———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »